Phibro Animal Health Corporation reported record net sales of more than $1.5 billion for fiscal 2026, with adjusted EBITDA up 39% to $255 million, and issued fiscal 2027 guidance for net sales of $1.55 billion to $1.6 billion and adjusted EBITDA of $258 million to $268 million. In the fourth quarter, sales grew 5% and adjusted EBITDA grew 29%, driven by strong performance in Mineral Nutrition and the legacy Animal Health business. The company also announced the planned closure of its Chicago Heights manufacturing facility, which is expected to yield annual benefits of $15 million to $20 million starting in fiscal 2028. Guidance assumes minimal sales of virginiamycin in Brazil due to regulatory uncertainty, with a favorable outcome representing upside. CEO Dani Bendheim highlighted the successful integration of the acquired Zoetis MFA portfolio and the conclusion of the Phibro Forward transformation program.
Phibro Animal Health CorporationRecord sales and EBITDA, plus fiscal 2027 guidance, are positive financial results.
Zoetis Inc